Over a span of one week, preliminary results from late-stage clinical trials of two promising coronavirus vaccines have ushered in renewed hope in the fight against the pandemic.
Canada has already secured up to 358 million doses of COVID-19 vaccines from a wide range of different manufacturers. But how will the vaccines be distributed and with limited supplies in the initial stages, who should get them first?
On Monday, U.S drugmaker Moderna announced that its vaccine has proven to be 94.5 per cent effective in protecting people from the COVID-19 disease, according to preliminary data. A week after Pfizer and BioNTech’s promising preliminary results of its Phase 3 trial, Pfizer confirmed on Wednesday its vaccine is 95 per cent effective, and has no serious side effects and protects older adults.
Mike Drolet looks at who will be the first in line for vaccinations, and why the rollout plan is anything but simple.
For more info, please go to [ Ссылка ]
Subscribe to Global News Channel HERE: [ Ссылка ]
Like Global News on Facebook HERE: [ Ссылка ]
Follow Global News on Twitter HERE: [ Ссылка ]
Follow Global News on Instagram HERE: [ Ссылка ]
#Coronavirus #COVID19 #Vaccine #GlobalNews
